Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Rheumatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Enteropathic arthritis

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Urgently assess a septic hot joint, painful photophobic eye, acute severe colitis, toxic megacolon, gastrointestinal bleeding, obstruction or venous thromboembolism. Immunosuppression can blunt fever, and new musculoskeletal symptoms may reflect infection or treatment toxicity rather than enteropathic inflammation.

Overview

Recognise peripheral and axial arthritis associated with inflammatory bowel disease, distinguish activity-linked from independent patterns, and coordinate treatment so joint control does not worsen intestinal disease.

Enteropathic arthritis is a spondyloarthritis associated most commonly with Crohn disease and ulcerative colitis. Arthritis can precede gastrointestinal diagnosis. Map joint distribution and tempo, entheses, dactylitis and inflammatory back pain, then compare them with objective bowel activity rather than stool frequency alone. Examine skin, nails and eyes and review family history and extra-intestinal manifestations.

Peripheral oligoarthritis often affects large lower-limb joints and may parallel bowel flares, whereas a more persistent polyarticular pattern can proceed independently. Axial disease and sacroiliitis also have an independent course. FBC, CRP, renal, liver and nutritional tests support severity; faecal calprotectin and endoscopy belong to bowel assessment; HLA-B27 modifies probability but does not diagnose the cause.

Treatment requires shared planning. Control active intestinal inflammation because this may improve activity-linked peripheral arthritis. Use physiotherapy and exercise for axial and entheseal disease. NSAID risks must be weighed with gastroenterology, especially during active IBD.

Aetiology

01

Inflammatory bowel disease

Crohn disease and ulcerative colitis share genetic, barrier and immune pathways with spondyloarthritis, allowing joint inflammation before or after bowel diagnosis.

02

Microbial and mucosal signalling

Altered intestinal barrier and microbiome exposure can activate lymphocyte trafficking and cytokine pathways across gut, enthesis and synovium.

03

Shared genetic susceptibility

HLA-B27 is most strongly associated with axial involvement, while other shared immune-barrier loci and cytokine pathways link inflammatory bowel disease with peripheral and axial spondyloarthritis.

Pathophysiology

  1. 1
    Gut–joint immune trafficking

    Activated immune cells and mediators generated at the intestinal barrier migrate or signal to synovial and entheseal tissues.

  2. 2
    Peripheral activity coupling

    Some acute peripheral oligoarthritis parallels bowel inflammation, while other polyarticular or axial patterns follow an independent disease course.

  3. 3
    Axial entheseal inflammation

    Sacroiliac, spinal and entheseal disease shares spondyloarthritis pathways and may progress despite good intestinal symptom control.

Clinical features and red flags

Activity-linked peripheral oligoarthritis

Acute asymmetric lower-limb synovitis that parallels bowel inflammation supports an enteropathic peripheral pattern and may improve with intestinal control.

Independent axial disease

Inflammatory back pain, sacroiliitis and restricted movement may persist despite bowel remission and require a dedicated axial treatment pathway.

Enthesitis or dactylitis

Insertional heel pain and whole-digit swelling provide spondyloarthritis evidence not captured by bowel symptoms or routine joint counts.

Septic-joint riskRed flag

Immunosuppression, biologic treatment, central access or systemic illness heightens concern for infection in one acutely hot joint.

Acute uveitisRed flag

Pain, photophobia, redness and visual change requires same-day ophthalmic review irrespective of current bowel or joint activity.

Investigations

  1. 01
    Integrated bowel and musculoskeletal assessmentFirst step
    Why
    Define whether peripheral, axial and entheseal activity parallels objective intestinal inflammation.
    Interpretation and limitations
    Symptoms in either domain may reflect damage or non-inflammatory disease; use examination and validated bowel assessment rather than assumed coupling.
  2. 02
    FBC, renal, liver, CRP, ESR and nutritional profile
    Why
    Assess inflammation, anaemia, organ status, deficiency and treatment safety.
    Interpretation and limitations
    CRP may arise from gut, joint or infection; anaemia and low albumin affect function and drug pharmacology and need causal assessment.
  3. 03
    Faecal calprotectin and gastrointestinal investigations
    Why
    Assess suspected active intestinal inflammation through the gastroenterology pathway.
    Interpretation and limitations
    Calprotectin is bowel-focused and does not measure joint activity; infection and NSAID exposure can affect results.
  4. 04
    Synovial-fluid culture and crystals
    Why
    Exclude infection and crystal disease in a new hot effusion.
    Interpretation and limitations
    Do not attribute an inflammatory count to IBD without culture; immunosuppression can reduce systemic and laboratory signals.

Differential diagnosis

01

Septic or crystal arthritis

One rapidly hot joint, fever, immunosuppression or dehydration requires aspiration for bacterial culture and crystals before assuming an IBD manifestation.

02

Medicine-related musculoskeletal disease

Corticosteroid osteonecrosis, fluoroquinolone tendon injury and selected biologic paradoxical inflammation can mimic or compound active arthritis.

03

Nutritional and metabolic bone disease

Vitamin D deficiency, osteomalacia, osteoporosis, anaemia and sarcopenia may cause bone pain, weakness or fracture distinct from synovitis.

04

Overlapping psoriatic or rheumatoid arthritis

Psoriasis with nail disease, rheumatoid serology or erosions, and a distribution discordant with bowel activity should prompt assessment for overlapping psoriatic arthritis, rheumatoid arthritis or another diagnosis.

Management

01Peripheral flare with bowel activityTreat gut and joint togetherFirst stepLower-limb synovitis occurs with objective intestinal inflammatory activity and no septic-joint signal.+
  1. 1Assess hydration, infection, bleeding, bowel severity and joint distribution and obtain appropriate blood, stool and synovial tests.
  2. 2Coordinate IBD treatment optimisation with gastroenterology and provide local or systemic joint symptom care that does not worsen bowel or renal risk.
  3. 3Reassess joint response after bowel control and refer persistent polyarthritis for conventional or targeted DMARD therapy.
02Axial or persistent arthritisChoose therapy across both domainsAxial, entheseal or peripheral disease remains active independently of intestinal symptoms.+
  1. 1Confirm active inflammation and separate osteonecrosis, osteoporosis, deficiency, infection and fibromyalgia using focused tests and imaging.

Complications

01

Persistent functional impairment

Classic inflammatory-bowel-disease-associated peripheral arthritis is usually non-erosive, but recurrent synovitis, enthesitis and dactylitis can still impair mobility and work; erosions should prompt reassessment for psoriatic arthritis, rheumatoid arthritis or another diagnosis.

02

Axial restriction and fracture

Chronic sacroiliac and spinal inflammation can cause ankylosis, osteoporosis, reduced mobility and unstable fracture after low-energy trauma.

03

Associated extra-intestinal inflammation

Uveitis and skin inflammation can threaten sight or require coordinated treatment, and their presence may determine which targeted class is safest across all active domains.

04

Therapeutic conflict and toxicity

An agent effective for joints may lack bowel efficacy or worsen IBD, while combined immunosuppression raises infection and drug-specific toxicity or malignancy risks.

Monitoring and follow-up

  • Measure bowel and musculoskeletal activity separately because response can diverge.
  • Follow FBC, renal, liver, albumin, iron and vitamin status according to disease and treatment.
  • Ask about infection, eye pain, skin disease, thrombosis symptoms and pregnancy plans at review.
  • Assess bone density and fracture risk after prolonged inflammation, malabsorption or corticosteroid exposure.
  • Coordinate biologic levels, switching and interruption with both gastroenterology and rheumatology rather than one domain alone.

Special situations

Joint activity may uncouple

Axial and persistent polyarticular disease can remain active while intestinal symptoms improve, requiring separate objective assessment.

Not every NSAID is harmless

Gastrointestinal mucosal, renal and bleeding risks matter particularly during active IBD or dehydration.

Drug class choice crosses specialties

A medicine effective for one joint domain may lack bowel efficacy or aggravate IBD, making shared selection essential.

Bone pain has alternatives

Osteoporosis, osteonecrosis, vitamin deficiency and steroid myopathy can mimic inflammatory musculoskeletal activity.

Infection signs can be muted

Immunosuppression may reduce fever and CRP, so local joint severity and host risk should drive aspiration.

Common pitfalls

  1. 01

    Assuming all joint symptoms parallel bowel activity.

  2. 02

    Using prolonged NSAIDs during active IBD without risk review.

  3. 03

    Choosing a targeted joint medicine without considering bowel efficacy or harm.

  4. 04

    Missing septic arthritis because immunosuppression blunts fever.

  5. 05

    Attributing steroid-related osteonecrosis or osteoporosis to an inflammatory flare.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RheumatologyOriginal SBA

Axial symptoms in bowel remission

A patient with Crohn disease in clinical remission has persistent inflammatory back pain and MRI-confirmed sacroiliitis. Which management principle is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Rheumatology topics →
Sources and review status8 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG65 spondyloarthritisRecognition and management of enteropathic spondyloarthritis.
  • NICE NG129 Crohn diseaseCrohn disease assessment and treatment.
  • NICE NG130 ulcerative colitisUlcerative colitis assessment and treatment.
  • BSR 2025 axial spondyloarthritis guidelineTargeted-class selection when active inflammatory bowel disease coexists.
  • Humira UK product informationIndication-specific adult induction, maintenance, contraindications and monitoring.
  • Sulfasalazine UK product informationAdult titration, contraindications and safety monitoring.
  • BSR pregnancy prescribing guidelineSulfasalazine, anti-TNF and exposure-specific infant-vaccine planning.
  • NICE CKS septic arthritisUrgent sampling and acute management of a hot joint.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Sulfasalazine
is an off-label, evidence-limited option for persistent peripheral arthritis and does not control axial inflammation. For active axial disease with active IBD, prefer a monoclonal TNF inhibitor or a JAK inhibitor whose exact indications and NICE status cover both conditions;
do not
start an IL-17 inhibitor.

Review competing causes: septic arthritis, Clostridioides difficile or other infection, corticosteroid osteonecrosis, osteoporosis, vitamin deficiency, fibromyalgia and medication toxicity. Avoid repeated systemic corticosteroid courses that increase infection, metabolic and bone harm. Coordinate vaccination, pregnancy planning, surveillance and treatment interruption during serious infection.

Key points

  • Inflammatory bowel disease may cause activity-linked asymmetric lower-limb oligoarthritis, more persistent small-joint polyarthritis, enthesitis, dactylitis or axial spondyloarthritis.
  • Ask whether joint symptoms track bowel activity, but do not assume controlled diarrhoea excludes active axial or peripheral disease.
  • Examine joints, entheses, digits and spine and ask about uveitis, psoriasis, bleeding, weight loss, perianal disease and current IBD medicines.
  • A hot joint in an immunosuppressed patient needs aspiration and culture; infection and crystals remain possible despite a convincing enteropathic history.
  • NSAIDs can worsen gastrointestinal symptoms or mucosal disease in some patients, so any trial should be cautious, short and coordinated when IBD is active.
  • Conventional DMARDs may help persistent peripheral arthritis but do not reliably control axial disease.
  • For active axial spondyloarthritis with active IBD, prefer a monoclonal TNF inhibitor or an exact JAK inhibitor licensed and NICE-recommended for both diagnoses; do not start an IL-17 inhibitor. Etanercept and gut-directed IL-12/23, IL-23 or integrin therapy do not reliably control axial inflammation; JAK use also needs cardiovascular, thrombotic, cancer, infection and pregnancy risk review.
05
Sacroiliac imaging
Why
Evaluate persistent inflammatory axial symptoms using the NICE radiography and MRI sequence.
Interpretation and limitations
Normal markers or radiographs do not exclude early axial disease, and bowel control does not determine imaging activity.
2
Choose targeted treatment jointly with gastroenterology. In active IBD, prefer a monoclonal TNF inhibitor or a specifically licensed and NICE-recommended JAK inhibitor for both conditions; do not start an IL-17 inhibitor, and do not rely on etanercept or gut-led IL-12/23, IL-23 or integrin therapy to control axial inflammation.
  • 3Screen infection, update vaccines and monitor joint, bowel, skin and eye outcomes separately after treatment begins.
    • 03Immunosuppressed hot jointAssume infection until sampledA patient with IBD on corticosteroid, immunomodulator or biologic develops one acutely hot restricted joint.+
    1. 1Perform urgent sepsis assessment, blood cultures and synovial culture plus crystals with acute orthopaedic and microbiology involvement.
    2. 2Withhold or continue immunosuppression only according to the responsible specialist and treatment pathway; do not intensify it reflexively.
    3. 3Secure source control, act on final cultures and coordinate safe restart after clinical recovery.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    Off-label conventional DMARD option under rheumatology for persistent peripheral enteropathic arthritis; evidence is limited and it does not treat axial inflammation.

    Sulfasalazine

    Start 500 mg once daily and increase the total daily dose by 500 mg each week as tolerated, usually to 1 g twice daily, under the specialist monitoring plan.

    Check baseline and serial FBC, liver and renal function; stop and seek urgent review for rash, fever, sore throat, bruising or jaundice. Withhold during a serious infection until recovery and specialist review. Check sulfonamide or salicylate allergy, G6PD risk and azathioprine or 6-mercaptopurine interaction; in pregnancy use folic acid 5 mg daily through the first trimester.

    Monoclonal TNF inhibitor that can treat active Crohn disease or ulcerative colitis and associated peripheral or axial spondyloarthritis.

    Adalimumab

    Ulcerative colitis: 160 mg at week 0, 80 mg at week 2, then 40 mg subcutaneously every other week from week 4. Crohn disease: 80/40 mg, or 160/80 mg when rapid response is required with greater adverse-event risk, then 40 mg every other week from week 4.

    Do not start during active TB or another serious infection; screen for TB and hepatitis B and review demyelinating disease. Adalimumab is contraindicated in NYHA III or IV heart failure and should stop for new or worsening failure. Avoid live vaccine during therapy; if continued beyond 28 weeks of pregnancy, BSR advises deferring infant live vaccines until 6 months.

    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Monitor nutrition, anaemia, bone health, thrombosis, infection and corticosteroid exposure alongside bowel and joint activity.